Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase for recent branch retinal vein occlusion
ACTRN12615000185561Phase 2Terminated
- Sponsor
- Lions Eye Institute
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tenecteplase in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Lions Eye Institute. Primary endpoints: Presence of intravascular thrombus and Venous outflow in the affected vein. Started Jan 2016; status: terminated.
02
Drugs
tenecteplase
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ACTRN12615000185561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000185561.